SAB Biotherapeutics (SABS) Operating Expenses (2020 - 2026)

SAB Biotherapeutics has reported Operating Expenses for 7 years, with the latest figure at $20.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 85.64% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (up 36.35% YoY), and the FY2025 full-year result was $49.0 million, up 10.67% from the prior year.
• Operating Expenses for Q1 2026 stood at $20.0 million, up from $15.8 million in the prior quarter.
• The five-year high for Operating Expenses was $20.0 million in Q1 2026, with the low at $6.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $12.1 million across 5 years, with a median of $11.3 million in 2024.
• The largest YoY upside for Operating Expenses was 91.39% in 2023 against a maximum downside of 56.87% in 2023.
• SAB Biotherapeutics' Operating Expenses stood at $10.0 million in 2022, then jumped by 91.39% to $19.2 million in 2023, then sank by 47.21% to $10.1 million in 2024, then jumped by 55.78% to $15.8 million in 2025, then advanced by 26.81% to $20.0 million in 2026.
• The last three Operating Expenses figures came in at $20.0 million (Q1 2026), $15.8 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.